https://www.selleckchem.com/pr....oducts/mitomycin-c.h
Tumor growth, gene mutation status, as well as protein and protein-phosphoprotein changes, were analyzed. RESULTS 100% of the 15 PDX tumors exhibited significant growth inhibition either in response to KRT-232 alone or in combination with BRAF and/or MEK inhibitors. Only BRAFV600wt tumors responded to KRT-232 treatment alone while BRAFV600E/M PDXs exhibited a synergistic response to the combination of KRT-232 and BRAF/MEK inhibitors. CONCLUSIONS KRT-232 is an effective therapy for the treatment of either BRAFwt or PANwt (BRAFwt, NRA